MetaboloStasis Therapeutics is a medical research and development company dedicated to the scientific advancement and development of therapeutic solutions for human metabolic diseases. With type 2 diabetes reaching pandemic levels in the U.S., MetaboloStasis Therapeutics distinguishes itself within the BioPharma milieu through equal resource allocation to R&D in Rare Metabolic Diseases, hitherto a neglected patient cohort. Our mission is simple: every life is worth the battle in the war against human disease.
The company was funded a $5,000 Preliminary Research Data award to purchase a number of human immortalized cell lines derived from patients with diagnosed diseases of copper homeostasis. These reagents will provide solid proof-of-concept data regarding the experimental feasibility of the research outlined in the SBIR proposal which was lacking in my previous NIH submission.
Learn more about MetaboloStasis Therapeutics by visiting our blog.